Diabetes

Study Provides Estimates of US Prevalence of Type 1, 2 Diabetes

September 21, 2018

The researchers found that 6317 adults received a diagnosis of diabetes. Among US adults, the weighted prevalence of diagnosed diabetes, type 1 diabetes, and type 2 diabetes was 9.7, 0.5, and 8.5%, respectively.

Gestational Diabetes Tied to Subsequent Glucose Disorders

September 20, 2018

"Gestational diabetes defined by criteria that identify a larger group of women was associated with a maternal disorder of glucose metabolism," the authors write.

FDA to Review Eylea for the Treatment of Non-Proliferative Diabetic Retinopathy

By September 14, 2018

The sBLA includes results from the Phase 3 PANORAMA trial, which enrolled 402 patients with NPDR.

Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

By September 11, 2018

The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.

Cost a key consideration of WHO guidelines for diabetes treatment intensification

September 06, 2018

WHO guidelines recommend selecting sulfonylureas as the single best second-line agent for Type 2 Diabetes Mellitus (T2DM) patients.

WHO Issues Recommendations for Tx Intensification in T2DM

September 05, 2018

"The decision to name sulfonylureas as the single best second-line agent largely reflects the prioritization of cost and the recognition that WHO guidelines must apply to low-resource settings," write the authors of an accompanying editorial.

FDA: Cases of Rare Gangrene of Genital Area Tied to Diabetes Drug Class

By August 30, 2018

The infection developed within several months of the patients starting SGLT2 therapy and the drug was discontinued in most cases. All patients required surgery and there was 1 reported death.

Increased First-Trimester HbA1c Predicts Gestational Diabetes

August 24, 2018

The researchers found that women who later developed GDM had significantly higher HbA1c at 8 to 13 gestational weeks than women without GDM (5.3 vs 5.1%).

Oral Semaglutide Appears Safe, Effective in T2D Patients With Renal Impairment

By August 20, 2018

PIONEER 5 (N=324) was a randomized, double-blind, placebo-controlled, parallel-group, 26-week trial that evaluated the safety and efficacy of oral semaglutide 14mg vs placebo in patients with type 2 diabetes and moderate renal impairment (eGFR 30 to 59mL/min/1.73m2) inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.

Low-Energy Diet Induces Different Effects in Men, Women

August 15, 2018

Men had larger reductions in metabolic syndrome Z-score, C-peptide, fat mass, heart rate

Newer and older insulin formulations offer similar glucose-lowering effect

August 09, 2018

Basal insulin analogues do not differ significantly in providing glucose control.

Thyroid Dysfunction Linked to Gestational Diabetes

August 07, 2018

The researchers found that both fT3 and fT3-to-fT4 ratio were positively correlated with GDM (adjusted odds ratios, 4.25 and 3.89 comparing the highest versus the lowest fT3 quartile at first and second trimester, respectively).

Plasma Copeptin More Accurate for Diabetes Insipidus Diagnosis

August 06, 2018

"This prospective evaluation of patients with hypotonic polyuria validated hypertonic saline-stimulated copeptin measurement as a diagnostic method that appeared to be superior to the indirect water-deprivation test in distinguishing central diabetes insipidus from primary polydipsia," the authors write.

Nut Intake Reduces HbA1c Among Adults With T2DM

August 03, 2018

The researchers found that the full-dose nut diet provided 9.2% greater total energy intake from monounsaturated fat compared with the full-dose muffin diet.

Insulin analogs not tied with reduced hypoglycemia compared to NPH

August 02, 2018

In this retrospective cohort study, for patients with type 2 diabetes, initiation of a basal insulin analog compared with NPH insulin was not associated with a reduced risk of hypoglycemia-related ED visits or hospital admissions.

One in Four Older Adults With Diabetes Uses Alternative Meds

July 31, 2018

The researchers found that more than 2 million older adults with diabetes (25.0%) used some form of CAM in the past year in 2012.

FDA Approves FreeStyle Libre 14 Day Flash Glucose Monitoring System

By July 30, 2018

The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear.

Sulfonylureas As 2nd-Line T2DM Therapy Tied to Higher Event Risk

July 24, 2018

The researchers found that over a mean follow-up of 1.1 years, sulfonylureas were associated with an increased risk of myocardial infarction, all-cause mortality, and severe hypoglycemia vs continuing metformin monotherapy.

Empagliflozin Does Not Up Risk of Bone Fractures

July 20, 2018

The researchers found that in the pooled analysis, bone fracture AEs were reported in 119 of 4221 patients (2.8%) randomized to empagliflozin 10mg, 105 of 4,196 patients (2.5%) randomized to empagliflozin 25mg, and 123 of 4203 patients (2.9%) randomized to the placebo group.

Results From Long-Term Cardiovascular Safety Study of Lorcaserin Announced

By July 19, 2018

Approximately 12,000 patients took part in the CAMELLIA-TIMI 61 trial in which participants were randomized to either lorcaserin HCl 10mg twice daily or placebo.

Trulicity Labeling Updated to Include Data on T2D Patients With CKD

By July 19, 2018

In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.

New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D

By July 19, 2018

Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.

Basal Insulin Analogues Similar for Glucose Lowering

July 18, 2018

Thrice-weekly degludec (Deg-3TW) was inferior to most other regimens for reducing glycated hemoglobin levels, according to low- to very-low-quality evidence.

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

By July 17, 2018

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.

FDA Extends Review Time for Invokana MACE Indication

By July 16, 2018

The application also includes the fixed-dose combinations, Invokamet (canagliflozin, metformin tablets) and Invokamet XR (canagliflozin, metformin extended-release tablets).

Two Regimens Fail to Stop Declines in β-Cell Function

July 13, 2018

The researchers observed no significant differences between treatment groups at baseline, 12 months, or 15 months in β-cell function, body mass index (BMI) percentile, hemoglobin A1c (HbA1c), fasting glucose, or oral glucose tolerance test 2-hour glucose results.

Does Basal Insulin Analog Use Reduce Hypoglycemia-Linked ER Visits?

July 13, 2018

No reduced risk of hypoglycemia-linked ER visits, admissions for basal insulin analog vs. NPH insulin

Circadian System, Misalignment Have Distinct Impact on Insulin

July 11, 2018

The researchers found that circadian phase and circadian misalignment impact glucose tolerance through different mechanisms.

FDA Strengthens Warnings for Fluoroquinolone Antibiotics

By July 10, 2018

The labeling changes are based on a review of postmarketing adverse event reports found in the FDA Adverse Event Reporting System (FAERS) database and published medical literature.

Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes

By July 10, 2018

For this study, researchers conducted a randomized, double-blind, placebo-controlled Phase 2 trial (N=24) to assess the efficacy and safety of adding oral verapamil for 12 months to a standard insulin regimen in adults with recent-onset type 1 diabetes (age range: 18 to 45 years).